Subscribe to RSS
DOI: 10.1055/s-0038-1624957
Verteilungsstudie mit 57Co-, 51Cr-, 111In- und 99mTc-Bleomycin in Mäusen mit einem soliden Ehrlich-Karzinom[*]
Distribution Study of 57Co- , 51Cr-, 111In - and 99mTc-Bleomycin in Solid Ehrlich-Carcinoma-Bearing MicePublication History
Eingegangen:03 March 1976
Publication Date:
11 January 2018 (online)
Zusammenfassung
Anhand der Verteilungsstudie von 57Co-, 51Cr-, 111In-und 99mTc-Bleomycin an 282 Mäusen mit einem soliden Ehrlich-Karzinom ist 57Co-Bleomycin am besten zur allgemeinen Tumorszintigraphie geeignet. Die Beobachtung über einen nahezu linearen 111In-Einbau in das Tumorgewebe (8—48 Std. post in-jektionem) stellt möglicherweise ein Hilfsmittel zur Objektivierung histologischer Differenzen und therapeutischer Maßnahmen im malignen Gewebe dar.
From the comparative studies of 57Co- , 51Cr- , 111Inand 99mTc-Bleomycin using 282 solid Ehrlich-carcinoma-bearing mice, 57Co was found to be the most suitable bleomycin preparation for tumorscintigraphy.
The results obtained by 111In-Bleomycin of linear tumor cell absorption indicates a possible use of 111In-Bleomycin as an agent for objective histological differentiation also in cells previously treated with therapeutic agents.
* Mit Unterstützung des Schweiz. Nationalfonds.
-
Literatur
- 1 Eckelmann W. C, Rzeszotarski W. J, Siegel B. A, Kusota H, Meena C, Stevenson J, Reba R. C. Chemical and biologic properties of isolated radiolabeled Bleomycin preparations. J. Nucl. Med 1975; 16: 1033-1037.
- 2 Grove R. B, Reba R. C, Eckelmann W. C, Goodyear M. Clinical evaluation of radiolabeled Bleomycin (Bleo) for tumor detection. J. Nucl. Med 1974; 15: 386-390.
- 3 Grove R. B, Eckelmann W. C, Reba R. C. Distribution of labeled Bleomycin in normal and tumor-bearing mice. J. Nucl. Med 1973; 14: 917-919.
- 4 Higashi T, Kanno M, Tomura K. Comparison of uptake of 67Ga-Citrate and 57Co-Bleomycin in tumor using a semiconductor detector. J. Nucl. Med 1974; 15: 1167-1170.
- 5 Lin M. S, Goodwin D. A, Kruse S. L. Bleomycin as a 99mTc carrier in tumor visualization. J. Nucl. Med 1974; 15: 338-342.
- 6 Orii H, Hiyoshimaru O. RI — labeled Bleomycins — a critical investigation on their stability in vitro and in vivo. Recent Advances in Nuclear Medicine, Proceedings of the First World Congress of Nuclear Medicine. 1974: 931-933.
- 7 Oyamada H, Ishibashi H, Orii H. Clinical experience of tumor seeking agents after Ga-67 citrate and the comparison between them. Recent Advances in Nuclear Medicine, Proceedings of the First World Congress of Nuclear Medicine. 1974: 707-709.
- 8 Robert J, Renault H, Rapin J, Rudler M, Nouel J. P. Métabolisme de la bléomycine marquée du cobalt 57 chez la souris. Thérapie 1973; 28: 933-940.
- 9 Robbins P. J, Silberstein E. B, Fortman D. L. The preparation and distribution of 111In-Bleomycin in mice as compared to 111In Cl3 for tumor scanning. J. Nucl. Med 1973; 14: 637.
- 10 Robbins P. J, Silberstein E. B, Fortman D. L. 111In-Bleomycin kinetics in mice bearing transplantable tumors of lung, skin and bone. J. Nucl. Med 1974; 15: 273-277.
- 11 Thakur M. L, Merrick M. V, Gunasekera S. W. Some pharmacological aspects of a new radiopharmaceutical, indium-Ill bleomycin. Radiopharmaceuticals and labelled compounds 1974; 2: 183-193. (Vienna).
- 12 Yeh S. D. J, Grando R, Young C. W, Benna R. S. Studies of indium labeled Bleomycin in man and in experimental animals. Recent Advances in Nuclear Medicine, Proceedings of the First World Congress of Nuclear Medicine. 1974: 928-930.